I agree that the company shouldn't respond to basher's. However, I do believe the company owes its investors information about what's happening there. It cannot discuss trials being done under double blind conditions, it can however update the trial database indicating enrollment, protocol changes, and new target dates for completion. This database hasn't been updated since last November.


Gary